FDA Issues Warning to Bausch & Lomb

U.S. regulators have warned Bausch & Lomb Inc. about alleged quality-control problems at one of its plants, including the presence of paint chips in rooms where sterile eye-care products were made.

The letter from the Food and Drug Administration said the Rochester, N.Y.-based company failed to adequately investigate the cause of the flaking paint and to take appropriate action.

A company spokeswoman said there was no evidence that paint chips made their way into any products.

Bausch & Lomb shares fell 3.9%, or $1.26, to $30.82 on the NYSE.